Relatlimab and nivolumab in the treatment of melanoma

Combined LAG-3 and PD-1 blockade is an emerging strategy for the treatment of melanoma. Tawbi et al. and Amaria et al. report in The New England Journal of Medicine and Nature respectively on two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic, and resectable, high-risk, node positive melanoma.

Automated summary

Combined LAG-3 and PD-1 blockade is a promising strategy in treating melanoma. Two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic and resectable high-risk melanoma with positive lymph nodes, have been reported in The New England Journal of Medicine and Nature respectively.